SMSPHARMA SMS Pharmaceuticals Q4 FY25 results (Jan–Mar 2025) and concall
SMS Pharma delivered a strong Q4 and FY25, with PAT growing 39% and revenue showing significant recovery. The company's focus on backward integration, product mix optimization, and cost efficiencies drove margin expansion. Management provided optimistic FY26 guidance, projecting 20% revenue growth and 20% EBITDA margins, supported by planned capex, while acknowledging challenges related to high inventory levels for commodity products.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 197 | 173 | 248 |
| EBITDA | 31 | 33 | 41 |
| Net profit | 14 | 18 | 20 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
